IQVIA and Genomics England will be offering a new solution for researchers to develop custom clinical–genomic data sets.

A partnership between IQVIA and Genomics England has been formed to provide data to researchers involved in drug development and personalized medicine. 

IQVIA was created following the merger of IMS Health and Quintiles. Genomics England is owned by the UK Department of Health and Social Care and was established to sequence 100,000 whole genomes from National Health Service (NHS) patients and their families. 

The system is based on IQVIA’s E360 platform and will include Genomics England’s de-identified, patient-consented data. The intention is for authorized academic and commercial researchers to be able to create custom clinical–genomic data sets and analyze genetic links to observable traits, initially for patients with rare diseases and their families, as well as patients with common cancers.

Through the partnership with IQVIA, Genomics England hopes to support research including genomic association studies, comparative efficacy and safety trials and burden-of-illness and discovery analytics. IQVIA customers, meanwhile, will be able to offer genomic testing to patients in parallel or as part of their clinical programs.